Drug Profile

EDP 235

Alternative Names: Direct acting antivirals - Enanta Pharamceuticals; EDP-235

Latest Information Update: 30 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enanta Pharmaceuticals
Class Antivirals; Small molecules
Mechanism of Action Coronavirus 3C-like proteinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II COVID 2019 infections

Most Recent Events

29 Jun 2023 Enanta Pharmaceuticals completes the phase II SPRINT trial in COVID-2019 infections, in USA and Romania (PO) (NCT05616728)
08 May 2023 EDP 235 is available for licensing as of 08 May 2023
08 May 2023 Efficacy, safety and pharmacokinetic data from a phase II SPRINT trial in COVID-19 infections released by Enanta pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com